A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis
commitment to ensuring the safety of patients with a bleeding disorder
Two investigators (HW and TG) independently performed the data extraction from each publication using a standardized form: publication data, baseline characteristics of the study population (sample size, sex, age, body mass index (BMI), body weight, abdominal circumference, waist-to-hip ratio, visceral adipose tissue (measured by computed tomography, magnetic resonance imaging, or dual-emission X-ray absorptiometry)), duration of follow-up, weight change during treatment and after treatment discontinuation, description of the weight management group and control group
Upptck mer
Just a small trick to get the perfect precision for your perfect pout